Wei Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wei Yan has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Nengming Lin
Department of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, China
2 shared publications Bo Zhang
Hangzhou Translational Medicine Research Center, Hangzhou First People's Hospital, Nanjing Medical University, Hangzhou, Zhejiang, 310006, China
1 shared publicationChao Lu
College of Pharmacy, Jinan University, Guangzhou 511443, China
1 shared publication- Chong Zhang
Department of Pharmacy, School of Medicine, Hangzhou City University, Hangzhou, Zhejiang, 310015, China; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, Hangzhou city University, Hangzhou, 310015, China
1 shared publication - Dan Liu
Shanghai AB Sciex Analytical Instrument Trading Co, Ltd, Shanghai, China
1 shared publication - Daojun Liu
Department of Pharmacy, Shantou University Medical College, Shantou 515041, China
1 shared publication
Latest Publications
- Open Access
- 30 January 2025
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 47 (5) , 619-624
Real-world Plasma Exposure of Nirmatrelvir/Ritonavir in Chinese Hospitalized Patients With COVID-19: A Multicenter Retrospective Study
Background: Nirmatrelvir/ritonavir is licensed for the treatment of mild-to-moderate coronavirus disease (COVID-19) in patients at an increased risk of progression to severe disease. However, data on the real-world plasma exposure to nirmatrelvir/ritonavir remain limited, particularly in Chinese patients. This study aimed to assess the nirmatrelvir/ritonavir trough concentration (Ctrough) and identify its critical factors in hospitalized Chinese patients treated with nirmatrelvir/ritonavir 300 mg/100 mg twice daily over a 5-day course. Methods: A high-performance liquid chromatography-tandem mass spectrometry assay was developed and validated to measure the nirmatrelvir/ritonavir Ctrough. Correlation analyses were performed to identify the variables influencing nirmatrelvir/ritonavir Ctrough. Results: Among the 110 patients, 100% had plasma concentrations above the antiviral in vitro 90% effective concentration. The median Ctrough of nirmatrelvir was 4.55 mcg/mL (15.6× 90% effective concentration), ranging from 0.65 to 12.44 mcg/mL. Nirmatrelvir Ctrough in normal and mild renal impairment cohorts were comparable (4.09 ± 1.97 mcg/mL and 4.57 ± 2.21 mcg/mL) but significantly increased in the moderate renal impairment cohort (6.41 ± 2.31 mcg/mL). Sex, age, and obesity were not significantly associated with nirmatrelvir exposure. Conclusions: Nirmatrelvir Ctrough was high in Chinese patients with COVID-19, and therapeutic drug monitoring should not be routinely recommended, except in patients with renal impairment.
- 30 January 2025
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 47 (5) , 619-624
Open AccessReal-world Plasma Exposure of Nirmatrelvir/Ritonavir in Chinese Hospitalized Patients With COVID-19: A Multicenter Retrospective Study
Background: Nirmatrelvir/ritonavir is licensed for the treatment of mild-to-moderate coronavirus disease (COVID-19) in patients at an increased risk of progression to severe disease. However, data on the real-world plasma exposure to nirmatrelvir/ritonavir remain limited, particularly in Chinese patients. This study aimed to assess the nirmatrelvir/ritonavir trough concentration (Ctrough) and identify its critical factors in hospitalized Chinese patients treated with nirmatrelvir/ritonavir 300 mg/100 mg twice daily over a 5-day course. Methods: A high-performance liquid chromatography-tandem mass spectrometry assay was developed and validated to measure the nirmatrelvir/ritonavir Ctrough. Correlation analyses were performed to identify the variables influencing nirmatrelvir/ritonavir Ctrough. Results: Among the 110 patients, 100% had plasma concentrations above the antiviral in vitro 90% effective concentration. The median Ctrough of nirmatrelvir was 4.55 mcg/mL (15.6× 90% effective concentration), ranging from 0.65 to 12.44 mcg/mL. Nirmatrelvir Ctrough in normal and mild renal impairment cohorts were comparable (4.09 ± 1.97 mcg/mL and 4.57 ± 2.21 mcg/mL) but significantly increased in the moderate renal impairment cohort (6.41 ± 2.31 mcg/mL). Sex, age, and obesity were not significantly associated with nirmatrelvir exposure. Conclusions: Nirmatrelvir Ctrough was high in Chinese patients with COVID-19, and therapeutic drug monitoring should not be routinely recommended, except in patients with renal impairment.
- 26 April 2023
- Published by Elsevier in Drug Discovery Today
- Vol. 28 (6) , 103598
Nanostructured organic photosensitizer aggregates in disease phototheranostics
- 26 April 2023
- Published by Elsevier in Drug Discovery Today
- Vol. 28 (6) , 103598
Nanostructured organic photosensitizer aggregates in disease phototheranostics
- 1 December 2021
- Published by Elsevier in International Immunopharmacology
- Vol. 101 (Pt A) , 108297
The role of P2X7 receptor in infection and metabolism: Based on inflammation and immunity
- 1 December 2021
- Published by Elsevier in International Immunopharmacology
- Vol. 101 (Pt A) , 108297
The role of P2X7 receptor in infection and metabolism: Based on inflammation and immunity
- 1 April 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 498 (3) , 481-486
Evodiamine induces apoptosis and promotes hepatocellular carcinoma cell death induced by vorinostat via downregulating HIF-1α under hypoxia
- 1 April 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 498 (3) , 481-486
Evodiamine induces apoptosis and promotes hepatocellular carcinoma cell death induced by vorinostat via downregulating HIF-1α under hypoxia